A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Merus N.V. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 6,017 shares of MRUS stock, worth $270,163. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,017
Previous 6,586 8.64%
Holding current value
$270,163
Previous $389,000 22.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$47.19 - $58.84 $26,851 - $33,479
-569 Reduced 8.64%
6,017 $300,000
Q2 2024

Aug 12, 2024

SELL
$39.81 - $60.2 $122,813 - $185,717
-3,085 Reduced 31.9%
6,586 $389,000
Q1 2024

May 09, 2024

SELL
$28.03 - $51.82 $12,417 - $22,956
-443 Reduced 4.38%
9,671 $435,000
Q4 2023

Feb 08, 2024

SELL
$20.06 - $28.66 $66,839 - $95,495
-3,332 Reduced 24.78%
10,114 $278,000
Q3 2023

Nov 07, 2023

BUY
$20.13 - $27.29 $26,370 - $35,749
1,310 Added 10.79%
13,446 $317,000
Q2 2023

Aug 09, 2023

SELL
$18.33 - $27.18 $80,248 - $118,994
-4,378 Reduced 26.51%
12,136 $319,000
Q1 2023

May 08, 2023

BUY
$14.25 - $20.5 $16,273 - $23,411
1,142 Added 7.43%
16,514 $303,000
Q4 2022

Feb 07, 2023

SELL
$12.8 - $23.66 $2,035 - $3,761
-159 Reduced 1.02%
15,372 $237,000
Q3 2022

Nov 01, 2022

BUY
$18.64 - $28.93 $5,126 - $7,955
275 Added 1.8%
15,531 $311,000
Q2 2022

Aug 04, 2022

BUY
$13.98 - $29.25 $55,766 - $116,678
3,989 Added 35.4%
15,256 $345,000
Q1 2022

May 09, 2022

BUY
$23.58 - $30.91 $26,032 - $34,124
1,104 Added 10.86%
11,267 $298,000
Q4 2021

Feb 07, 2022

SELL
$20.0 - $32.29 $33,180 - $53,569
-1,659 Reduced 14.03%
10,163 $314,000
Q2 2021

Aug 06, 2021

BUY
$20.0 - $25.48 $236,440 - $301,224
11,822 New
11,822 $249,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.06B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.